Ascentage Pharma Group International (HK:6855) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Ascentage Pharma Group International excitedly reports on the anticipated presentation of their latest clinical study results for three leading drug candidates at the 2024 American Society of Clinical Oncology Annual Meeting. These drugs include the China-approved olverembatinib and other investigational treatments targeting various cancers. The findings will be shared through oral reports and poster presentations, highlighting the company’s advancements in oncology.
For further insights into HK:6855 stock, check out TipRanks’ Stock Analysis page.